A Randomized Clinical Trial of Single-Dose Versus Weekly Dalbavancin for Treatment of Acute Bacterial Skin and Skin Structure Infection

Michael W Dunne, Sailaja Puttagunta, Philip Giordano, Dainis Krievins, Michael Zelasky, James Baldassarre, Michael W Dunne, Sailaja Puttagunta, Philip Giordano, Dainis Krievins, Michael Zelasky, James Baldassarre

Abstract

Background: Acute bacterial skin and skin structure infections (ABSSSIs) are a cause of significant morbidity and therapy can be a burden to the healthcare system. New antibiotics that simplify treatment and avoid hospitalization are needed. This study compared the safety and efficacy of a single intravenous infusion of 1500 mg of dalbavancin to the 2-dose regimen.

Methods: This study was a randomized, double-blind trial in patients aged >18 years with ABSSSIs. Patients were randomized to dalbavancin 1500 mg either as a single intravenous (IV) infusion or 1000 mg IV on day 1 followed 1 week later by 500 mg IV. The primary endpoint was a ≥20% reduction in the area of erythema at 48-72 hours in the intent-to-treat population. Noninferiority was to be declared if the lower limit of the 95% confidence interval (CI) on the difference in the outcomes was greater than -10%. Clinical outcome was also assessed at days 14 and 28.

Results: Six hundred ninety-eight patients were randomized. Demographic characteristics were similar on each regimen, although there were more patients with methicillin-resistant Staphylococcus aureus (MRSA) at baseline on the 2-dose regimen (36/210 [17.1%] vs 61/220 [27.7%]). Dalbavancin delivered as a single dose was noninferior to a 2-dose regimen (81.4% vs 84.2%; difference, -2.9% [95% CI, -8.5% to 2.8%]). Clinical outcomes were also similar at day 14 (84.0% vs 84.8%), day 28 (84.5% vs 85.1%), and day 14 in clinically evaluable patients with MRSA in a baseline culture (92.9% vs 95.3%) in the single- and 2-dose regimens, respectively. Treatment-emergent adverse events occurred in 20.1% of the single-dose patients and 19.9% on the 2-dose regimen.

Conclusions: A single 1500-mg infusion of dalbavancin is noninferior to a 2-dose regimen, has a similar safety profile, and removes logistical constraints related to delivery of the second dose.

Clinical trials registration: NCT02127970.

Keywords: clinical trial; dalbavancin; efficacy; methicillin-resistant Staphylococcus aureus; skin infection.

© The Author 2015. Published by Oxford University Press for the Infectious Diseases Society of America.

Figures

Figure 1.
Figure 1.
Disposition of patients and analysis sets. Abbreviation: ITT, intent to treat.

References

    1. Pallin DJ, Egan DJ, Pelletier AJ et al. . Increased US emergency department visits for skin and soft tissue infections, and changes in antibiotic choices, during the emergence of community-associated methicillin-resistant Staphylococcus aureus. Ann Emerg Med 2008; 51:292–8.
    1. David MZ, Medvedev S, Hohmann SF, Ewigman B, Daum RS. Increasing burden of methicillin-resistant Staphylococcus aureus hospitalizations at US academic medical centers, 2003–2008. Infect Control Hosp Epidemiol 2012; 33:782–9.
    1. David MZ, Daum RS, Bayer AS et al. . Staphylococcus aureus bacteremia at five U.S. academic medical centers, 2008–2011: significant geographic variation in community-onset infections. Clin Infect Dis 2014; 15:798–807.
    1. Liu C, Bayer A, Cosgrove SE et al. . Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18–55.
    1. Daum RS. Clinical practice. Skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. N Engl J Med 2007; 357:380–90.
    1. Andes D, Craig WA. In vivo pharmacodynamic activity of the glycopeptide dalbavancin. Antimicrob Agents Chemother 2007; 51:1633–42.
    1. Dorr MB, Jabes D, Cavaleri M et al. . Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide. J Antimicrob Chemother 2005; 55(suppl 2):ii25–30.
    1. Martinez MN, Papich MG, Drusano GL. Dosing regimen matters: the importance of early intervention and rapid attainment of the pharmacokinetic/pharmacodynamic target. Antimicrob Agents Chemother 2012; 56:2795–805.
    1. Farrington CP, Manning G. Test statistics and sample size formulae for comparative binomial trials with null hypothesis or non-zero risk difference or non-unity relative risk. Stat Med 1990; 9:1447–54.
    1. Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med 1985; 4:213–26.
    1. Boucher HW, Wilcox M, Talbot GH et al. . Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med 2014; 370:2169–78.
    1. Jauregui LE, Babazadeh S, Seltzer E et al. . Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis 2005; 41:1407–15.
    1. Dunne MW, Zhou M, Borje Darpo B. A thorough QT study with dalbavancin: a novel lipoglycopeptide antibiotic for the treatment of acute bacterial skin and skin-structure infections. Int J Antimicrob Agents 2015; 45:393–8.
    1. Tice AD, Rehm SJ, Dalvasio JR et al. . Practice guidelines for outpatient parenteral antimicrobial therapy. Clin Infect Dis 2004; 38:1651–72.
    1. Jenkins TC, Sabel AL, Sarcone EE, Price CS, Mehler PS, Burman WJ. Skin and soft-tissue infections requiring hospitalization at an academic medical center: opportunities for antimicrobial stewardship. Clin Infect Dis 2010; 51:895–903.
    1. Jenkins TC, Knepper BC, Sabel AL et al. . Decreased antibiotic utilization after implementation of a guideline for inpatient cellulitis and cutaneous abscess. Arch Intern Med 2011; 171:1072–9.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe